Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 μg ethinyl estradiol and 150 μg desogestrel in Latin-American women

Springer Science and Business Media LLC - Tập 14 - Trang 15-26 - 1998
M.R. Comparato1, J.A. Yabur2, M. Bajares3
1Hospital Juan A. Fernandez, Buenos Aires, Argentina
2Servicio de Ginecologia y Reproduccion Humana, Hospital Jose Ignacio Baldo, Caracas, Venezuela
3Servicio de Ginecologia, Hospital Clinico Universitario, Caracas, Venezuela

Tóm tắt

Contraceptive efficacy, subject acceptability (cycle control, side-effects, acne score and weight gain) and blood pressure of a monophasic oral contraceptive containing 30 μg ethinyl estradiol plus 150 μg desogestrel (Marvelon) were assessed in an open-label 6-cycle multicenter study in Argentina (7 centers) and Venezuela (5 centers). Of the 407 participating women, 389 (95.6%) completed six cycles of treatment, providing data for a total of 2383 cycles. No pregnancies occurred during the course of the study, confirming the high contraceptive reliability of Marvelon. Cycle control was excellent; the duration of withdrawal bleeding decreased during consecutive treatment cycles and the incidence of spotting and breakthrough bleeding was low. The desogestrel/ethinyl estradiol combination was well tolerated and the incidence of minor side-effects, which was already low in the first treatment cycle, in most cases decreased during the subsequent cycles. The preparation was effective in reducing pre-existing acne, whereas it did not induce clinically relevant changes in blood pressure and body weight. Marvelon was shown to provide effective oral contraception, with good tolerance and excellent cycle control in Latin-American women.

Tài liệu tham khảo

Halbe HW, Cunha DC, Diaz J et al. Clinical experience in Brazil with a desogestrel-containing oral contraceptive. In: Halbe HW, Rekers H, eds. Oral Contraception into the 1990s. Carnforth: Parthenon Publishing Group; 1989:69-74.

Comparato M, Bluvstein G, Dron N et al. Estudio multicentrico sobre 1.278 ciclos, del anticonceptivo oral monofasico combinado etinilestradiol/desogestrel. Sinop Obs Gin. 1993;40:39-44.